文献速递胸部肿瘤放疗放疗物理与技术

质子束治疗特发性肺纤维化合并非小细胞肺癌的前瞻性研究

Prospective study of proton beam therapy for non-small cell lung cancer patients with idiopathic pulmonary fibrosis.
PubMed 文献 · Radiother Oncol · 2026-06-18

这项前瞻性研究纳入55例(最终分析41例)特发性肺纤维化(IPF)合并非小细胞肺癌(NSCLC)患者,评估根治性质子束治疗(PBT)后的肺毒性和临床结局。中位随访21.6个月,≥3级肺毒性发生率为17.1%,临床III期患者显著高于I-II期(44.4% vs 9.4%,p=0.010)。早期患者结局可接受,但III期患者严重肺毒性仍较高,需谨慎选择患者。

要点

  • IPF合并NSCLC患者根治性PBT后≥3级肺毒性发生率为17.1%。
  • 临床III期患者≥3级肺毒性发生率显著高于I-II期(44.4% vs 9.4%,p=0.010)。
  • PBT后FVC、FEV1和DLCO随时间呈统计学显著下降。

核心结论

  • 根治性PBT对早期IPF合并NSCLC患者结局可接受,但III期患者严重肺毒性仍较高,支持谨慎选择患者。

研究设计与样本

  • 前瞻性研究,2020年6月至2023年8月入组55例,最终分析41例IPF合并NSCLC患者,主要终点为≥3级肺毒性。

主要发现

  • 中位随访21.6个月,7例(17.1%)发生≥3级肺毒性,其中4例(9.8%)为≥4级事件。
  • 临床I-II期患者≥3级肺毒性发生率为9.4%(3/32),III期为44.4%(4/9),差异有统计学意义(p=0.010)。
  • 1年总生存率为67.6%,1年局部区域控制率为93.2%。
  • PBT后FVC、FEV1和DLCO随时间呈统计学显著下降。

关键数值与推荐

  • 最常见处方剂量为64 GyE分8次(41.5%),中位生物有效剂量(α/β=10)为115.2 GyE(四分位距80.5-115.2)。
  • 基线预计FVC、FEV1和DLCO中位值分别为72.0%、80.0%和45.0%。
  • 性别-年龄-生理学分期I/II/III期分别为17.1%/70.7%/12.2%,临床分期I/II/III期分别为56.0%/22.0%/22.0%。

临床怎么用

  • 对IPF合并早期NSCLC患者可考虑根治性PBT,但需密切监测肺功能变化。
  • 对IPF合并III期NSCLC患者应充分评估严重肺毒性风险,谨慎选择PBT。

局限性

  • 最终分析样本量较小(41例),可能影响结果稳定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with idiopathic pulmonary fibrosis (IPF) are vulnerable to severe pulmonary toxicity after thoracic radiotherapy. We prospectively evaluated pulmonary toxicity and clinical outcomes after definitive proton beam therapy (PBT) for non-small cell lung cancer (NSCLC) with IPF. METHODS: From June 2020 to August 2023, 55 patients were enrolled and 41 were finally analyzed. The primary endpoint was grade ≥ 3 pulmonary toxicity (G3 + ). Secondary endpoints included pulmonary function changes, overall survival (OS), and quality of life. The most common prescribed dose was 64 GyE in 8 fractions (41.5%) with a median biologically effective dose (α/β = 10) of 115.2 GyE (interquartile range, 80.5-115.2). RESULTS: The median baseline predicted forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) were 72.0%, 80.0% and 45.0%, respectively. Gender-Age-Physiology stages I/II/III were 17.1%/70.7%/12.2%. Clinical stages I/II/III were 56.0%/22.0%/22.0%. During a median follow-up of 21.6 months, G3 + developed in 7 (17.1%) patients, including ≥ grade 4 events in 4 patients (9.8%). G3 + were observed in 3 of 32 patients (9.4%) with clinical stage I-II disease, compared to 4 of 9 patients (44.4%) with stage III disease (p = 0.010). One-year OS and locoregional control were 67.6% and 93.2%, respectively. Overall FVC, FEV1, and DLCO showed statistically significant declines over time after PBT. CONCLUSIONS: Definitive PBT for patients with NSCLC and IPF showed acceptable outcomes in early-stage disease; however, severe pulmonary toxicity remained substantial in stage III disease, supporting careful patient selection.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Shin H, Yang K, Yoo H, et al. Prospective study of proton beam therapy for non-small cell lung cancer patients with idiopathic pulmonary fibrosis. Radiother Oncol. 2026. PMID: 42314836. doi:10.1016/j.radonc.2026.111646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。